A Study of ADVATE in People With Hemophilia A in India

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-14

Study Completion Date

2023-02-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main aim of this study is to learn more about side effects of Advate when given as standard treatment to people with hemophilia A who have already been treated.

The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study. Participants will need to visit the study doctor 5 times in total during the study. During these visits, study data will be collected by the study doctor.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A

NCT02634723

Hemophilia A

COMPLETED

A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

NCT05707351

Hemophilia A

COMPLETED PHASE3

A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched From Other Factor VIII Treatments to Adynovate

NCT04876365

Hemophilia A

COMPLETED

A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A

NCT04158934

Hemophilia A

ACTIVE_NOT_RECRUITING

China ADVATE PTP Study

NCT02170402

Hemophilia A

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemophilia A

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hemophilia A Group

Participants with hemophilia A were treated with ADVATE according to a regimen determined by the treating physician at the study site and in accordance with the national product label under standard clinical practice for 6.7 months.

Group Type EXPERIMENTAL

ADVATE

Intervention Type BIOLOGICAL

Antihemophilic factor (AHF) activity expressed in international units (IU) per vial.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ADVATE

Antihemophilic factor (AHF) activity expressed in international units (IU) per vial.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The participant or legally authorized representative (in case of study participants less than (\<) 18 years of age) gave written informed consent to participate in the study.
* Participant of any age with hemophilia A.
* Participant defined as a previously treated patient (PTP):

* Participant aged greater than or equal to (\>=) 6 years that has been previously treated with plasma-derived and/or recombinant FVIII concentrate(s) for a minimum of 150 exposure doses (EDs).
* Participant aged less than \<6 years that has been previously treated with plasma-derived or recombinant FVIII concentrate(s) for a minimum of 50 EDs.
* Participant as negative history of FVIII inhibitors and negative inhibitor at screening defined as less than 0.6 Bethesda units (BU) per milliliter (Nijmegen-modified Bethesda assay).
* Participant is human immunodeficiency virus negative (HIV-); or human immunodeficiency virus positive (HIV+) with stable disease and cluster of differentiation 4 (CD4+) count \>=200 cells per cubic millimeter (mm\^3), as confirmed by central laboratory at screening.
* Participant is hepatitis C virus negative (HCV-) by antibody or polymerase chain reaction (PCR) testing (if positive, anti-body titer will be confirmed by PCR), as confirmed by central laboratory at screening; or hepatitis C virus positive (HCV+) with chronic stable hepatitis.
* Participant is willing and able to comply with the requirements of the protocol.

Exclusion Criteria

* Participant has known hypersensitivity to mouse or hamster proteins or to any of the excipients of FVIII (factor VIII) concentrates.
* Participant has been diagnosed with bleeding disorder(s) other than congenital hemophilia A, such as acquired hemophilia A, von Willebrand´s disease (VWD) or thrombocytopenia (platelet count \<100,000 per milliliter).
* Participant has received treatment for hemophilia A with non-FVIII products or concentrates (example, emicizumab \[Hemlibra®\]) in the 6 months prior to screening.
* Participant has severe chronic hepatic dysfunction (example, \>=5 times upper limit of normal alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] or international normalized ratio \[INR\] \>1.5 as confirmed by central laboratory at screening).
* Participant has planned or is likely to have, surgery during the study period.
* Participant has a clinically significant medical, psychiatric, or cognitive illness, or recreational drug or alcohol use that, in the opinion of the investigator, would affect participant's safety or compliance.
* Participant currently receiving or is scheduled to receive during the course of the study, an immunomodulating drug (example, corticosteroid agents at a dose equivalent to hydrocortisone \>10 milligram per day, or α-interferon) other than antiretroviral chemotherapy.
* Participant has participated in another clinical study involving an investigational product (IP) or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
* Participant is a family member or employee of the investigator.

Eligible Sex

ALL

Accepts Healthy Volunteers

No